Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187384
Title: | Adoptive NK Cell Transfer as a Treatment in Colorectal Cancer Patients: Analyses of Tumour Cell Determinants Correlating With Efficacy In Vitro and In Vivo |
Author: | Lanuza, Pilar M. Alonso Aguado, Maria Henar Hidalgo, Sandra Uranga Murillo, Iratxe García Mulero, Sandra Arnau, Raquel Santos, Cristina Sanjuan, Xavier Santiago, Llipsy Comas, Laura Redrado, Sergio Pazo Cid, Roberto Agustin Ferrández, M. Jose Jaime Sánchez, Paula Pesini, Cecilia Gálvez, Eva M. Ramírez Labrada, Ariel Arias, Maykel Sanz Pamplona, Rebeca Pardo, Julián |
Keywords: | Càncer colorectal Immunoteràpia Colorectal cancer Immunotheraphy |
Issue Date: | 7-Jun-2022 |
Publisher: | Frontiers Media |
Abstract: | BackgroundColorectal cancer (CRC) is a heterogeneous disease with variable mutational profile and tumour microenvironment composition that influence tumour progression and response to treatment. While chemoresistant and poorly immunogenic CRC remains a challenge, the development of new strategies guided by biomarkers could help stratify and treat patients. Allogeneic NK cell transfer emerges as an alternative against chemoresistant and poorly immunogenic CRC. MethodsNK cell-related immunological markers were analysed by transcriptomics and immunohistochemistry in human CRC samples and correlated with tumour progression and overall survival. The anti-tumour ability of expanded allogeneic NK cells using a protocol combining cytokines and feeder cells was analysed in vitro and in vivo and correlated with CRC mutational status and the expression of ligands for immune checkpoint (IC) receptors regulating NK cell activity. ResultsHLA-I downmodulation and NK cell infiltration correlated with better overall survival in patients with a low-stage (II) microsatellite instability-high (MSI-H) CRC, suggesting a role of HLA-I as a prognosis biomarker and a potential benefit of NK cell immunotherapy. Activated allogeneic NK cells were able to eliminate CRC cultures without PD-1 and TIM-3 restriction but were affected by HLA-I expression. In vivo experiments confirmed the efficacy of the therapy against both HLA(+) and HLA(-) CRC cell lines. Concomitant administration of pembrolizumab failed to improve tumour control. ConclusionsOur results reveal an immunological profile of CRC tumours in which immunogenicity (MSI-H) and immune evasion mechanisms (HLA downmodulation) favour NK cell immunosurveillance at early disease stages. Accordingly, we have shown that allogeneic NK cell therapy can target tumours expressing mutations conferring poor prognosis regardless of the expression of T cell-related inhibitory IC ligands. Overall, this study provides a rationale for a new potential basis for CRC stratification and NK cell-based therapy. |
Note: | Reproducció del document publicat a: https://doi.org/10.3389/fimmu.2022.890836 |
It is part of: | Frontiers in Immunology, 2022, vol. 13 |
URI: | http://hdl.handle.net/2445/187384 |
Related resource: | https://doi.org/10.3389/fimmu.2022.890836 |
ISSN: | 1664-3224 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fimmu-13-890836.pdf | 4.27 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License